News BridgeBio two for two as rare disease drug aces ph3 trial BridgeBio's week just went from great to superb, as it reports a second positive topline result in a pivotal trial of a late-stage pipeline drug.
News CRISPR biotech Intellia plummets as trial paused for safety Intellia lost 45% of its value today as phase 3 trials of one of its priority drug programmes were halted due to a patient being hospitalised.
News Pressure rises on Novo as Innovent drug tops Ozempic Innovent's dual glucagon and GLP-1 agonist mazdutide outperforms Novo Nordisk's Ozempic in overweight people with diabetes.
News George's triple therapy for hypertension hits mark in stroke George Medicines' new triple pill for hypertension delivers a much-needed win in a phase 3 trial in haemorrhagic stroke.
News Moderna drops mRNA jab for CMV after phase 3 fail Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital CMV infections, once touted as a future blockbuster.
News Alector ditches GSK-partnered dementia drug and cuts staff Alector has abandoned latozinemab as a treatment for frontotemporal dementia, four years after GSK licensed the antibody in a $700m upfront deal.
News FDA follows experts' advice and blocks Capricor DMD therapy The FDA has dashed Capricor's hope of getting approval for its cell therapy for Duchenne muscular dystrophy, wreaking havoc with its share price.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.